Clinical trials: Hepatitis, Viral, Human
Hepatitis B
Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response
GSK Biologicals' currently licensed multidose hepatitis B vaccine will be compared to the currently licensed monodose hepatitis B vaccine in a population with well documented hepatitis B immunological response to the vaccine…
- Trial name
- NCT00197158
- Testing
- Hepatitis B vaccine
- Where
- Belgium
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients
This is a prospective, randomized, multicenter, open-label study. After more than 24 weeks NA treatment, HBeAg positive CHB patients who achieved HBV DNA<1000copies/ml but HBeAb negative, will be randomized (1:1) into 2 study…
- Trial name
- NCT02474316
- Testing
- Peginterferon alfa-2a, nucleos(t)ide analgoue
- Where
- 3 sites in China
- Volunteers
- 366 people
- Sponsor
- Ruijin Hospital
Hepatitis C
TD-6450 SAD and MAD in Healthy Subjects
This study consists of two parts, Parts A and B. Part A is a single ascending dose (SAD) study in healthy subjects. Part B is a multiple ascending dose (MAD) study in healthy subjects.
- Trial name
- NCT02022306
- Testing
- TD-6450
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Hepatitis C
Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I
This is a treatment study trial, in which we will assess the safety and tolerability of daily dose IL-2, as monotherapy for 12 weeks, followed by IL2 in combination with PEG-IFN and RBV for 48 weeks in the treatment of chronic…
- Trial name
- NCT00277758
- Testing
- Interleukin 2, Ribavirin, Pegylated Interferon Alpha
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Weill Medical College of Cornell University
Chronic Hepatitis b
Finite Versus Continuous Nucleos(t)Ide Analogues for Chronic Hepatitis B
BACKGROUND: Finite nucleos(t)ide analogue (Nuc) therapy was proposed as an alternative strategy in the management of chronic hepatitis B (CHB) but there remained not data from randomized controlled trials to clarify safety and…
- Trial name
- NCT05793268
- Testing
- Nuc Discontinuation, Entecavir or Tenofovir
- Where
- 6 sites in Taiwan
- Volunteers
- 360 people
- Sponsor
- E-DA Hospital
Chronic Hepatitis C, Illicit Drug Use
Hepatitis C Treatment in Underserved Populations
The purpose of this study is to examine the feasibility, safety, and effectiveness of treating persons who are actively using illicit drugs for hepatitis C using a collaborative, multidisciplinary, integrated care model.
- Trial name
- NCT01717560
- Testing
- Collaborative, multidisciplinary, integrated care
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brian Edlin
Hepatitis B Virus, HBV
Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials
The purpose of this study is to provide entecavir to participants who have completed another entecavir trial without achieving virologic response or who relapsed during postdosing follow-up.
- Trial name
- NCT01438424
- Testing
- Entecavir, Lamivudine
- Volunteers
- 1,053 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation
The purpose of this study is to evaluate the effect of cyclosporine, an anti-rejection drug, on the clearance of the hepatitis C virus in liver transplant subjects being treated with peg-interferon and ribavirin.
- Trial name
- NCT00821587
- Testing
- Cyclosporine, Tacrolimus
- Volunteers
- 39 people
- Sponsor
- University of Florida
Chronic Hepatitis b
Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects
A Randomized, Double-Blind, Single-Center Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effects of Single and Multiple Doses of XT1061 in Healthy Subjects.
- Trial name
- XT1061 (NCT06280534)
- Where
- China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Hepatitis C, Chronic
A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)
This is a non-randomized, open-label, single-dose study to evaluate the pharmacokinetics (PK) of uprifosbuvir (MK-3682), the M5 and M6 metabolites of uprifosbuvir, and ruzasvir (MK-8408), in participants with moderate hepatic…
- Trial name
- NCT02666352
- Testing
- Uprifosbuvir, Ruzasvir
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus Infection
Relinking Diagnosed But Untreated HCV Patients Back Into Care.
Reintroduction of patients into a HCV infection care pathway after a positive chronic hepatitis C diagnosis by previous testing in our hospital who were lost in follow-up.
- Trial name
- Relink (NCT05975216)
- Testing
- Contact the patient
- Where
- Belgium
- Volunteers
- 600 people
- Sponsor
- Universitair Ziekenhuis Brussel
Hepatitis B
Prevalence of Hepatitis B in Vallés Occidental. Observational Multicentric Study
The aim of this study is to evaluate the prevalence of hepatitis B in Vallés Occidental. Also, describe the stage of the disease, and whether if they are under medical treatment or not.
- Trial name
- NCT02548325
- Testing
- Not apply
- Where
- Spain
- Volunteers
- 1,001 people
- Sponsor
- Corporacion Parc Tauli
Chronic Hepatitis C
Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C
Investigation of the usefullness of therapeutical drug monitoring of ribavirin for dose adaptation during combination therapy of chronic hepatitis C patients.
- Trial name
- NCT00209755
- Testing
- therapeutic drug monitoring of ribavirin and dose adaptation
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Hopital A Michallon
Hepatitis B
Cameroon HepB Birth Dose Feasibility Pilot
This feasibility assessment is to provide quantitative findings of an intervention integrating immunizations into maternity and newborn care across 15 health facilities in Cameroon.
- Trial name
- NCT04893616
- Testing
- Integration of vaccination services into delivery services
- Where
- 13 sites in Cameroon
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Clinton Health Access Initiative Inc.
Alcoholic Liver Disease, Chronic Hepatitis C Virus Infection
sgp130 in Chronic Human Liver Disease
Chronic liver disease are characterized by increased levels of plasma IL-6, but the bioactivity of this cytokine in this disease is not well known.
- Trial name
- NCT00770198
- Where
- Belgium
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Erasme University Hospital
Hepatitis B, HIV Infections
Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients
HBe seroconversion is an important goal for anti-HBV treatment, since it is associated with a non progressive liver infection and a better clinical outcome.
- Trial name
- HB01EMVIPEG (NCT00391638)
- Testing
- TRUVADA (EMTRICITABINE + TENOFOVIR DF), PEGASYS 180μg (Interféron pégylé alpha -2a)
- Where
- 2 sites in France
- Volunteers
- 56 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hemophilia, AIDS
Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)
Background: Over 80% of the hemophiliac population who became infected with HIV prior to 1985 are also co-infected with HCV. Thus, hemophiliacs represent an important population for studies of the natural history of these chronic…
- Trial name
- NCT00340548
- Where
- 15 sites in United States
- Volunteers
- 333 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Hepatitis B
NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients
The general objective of the present clinical trial is to compare the therapeutic efficacy of a combination therapeutic vaccine containing hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) [later called…
- Trial name
- NASVAC (NCT01374308)
- Testing
- NASVAC, Pegylated interferon alpha 2b
- Where
- Bangladesh
- Volunteers
- 160 people
- Sponsor
- Clinical Research Organization, Dhaka, Bangladesh
HIV Infections, Hepatitis C
The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin
This study will evaluate how controlling HIV infection with HAART (highly active antiretroviral therapy) affects the response to hepatitis C treatment with peginterferon alpha-2b and ribavirin in HIV-infected patients with…
- Trial name
- NCT00031343
- Testing
- highly active antiretroviral therapy (HAART)
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HCV Coinfection, Hepatitis C
Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens
The aim of this study is to evaluate RBV plasma concentrations when used in combination with newly developed DAA combinations. If possible, its correlations with SVR rates and incidence of anaemia will be assessed in HCV-patients.
- Trial name
- RIBACOP (NCT02505243)
- Where
- Netherlands
- Volunteers
- 252 people
- Sponsor
- Radboud University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.